Krystal Biotech, Inc. KRYS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s EPS (diluted)?
- Krystal Biotech, Inc. (KRYS) reported EPS (diluted) of $1.83 in Q1 2026.
- How has Krystal Biotech, Inc.'s EPS (diluted) changed year-over-year?
- Krystal Biotech, Inc.'s EPS (diluted) increased by 52.5% year-over-year, from $1.20 to $1.83.
- What is the long-term trend for Krystal Biotech, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s EPS (diluted) has grown at a 21.6% compound annual growth rate (CAGR), from -$3.13 to $6.85.
- What does EPS (diluted) mean?
- The profit per share assuming all potential sources of new shares are exercised.
- How do you interpret EPS (diluted)?
- A higher value indicates strong earnings even when accounting for potential dilution, signaling robust financial health.
- How does EPS (diluted) compare across companies?
- Standard metric for assessing shareholder value; essential for companies with complex capital structures.